Skip to content
Companies

Aethl Bio

Oxygen-delivering hydrogels for chronic wound care

Raised to date

$1.6M

of $5M offered across 1 Form D filing

Still open
$3.4M
Investors
8
Last filed
Apr 17, 2026

About

Aethl Bio is a Pittsburgh biotechnology company developing hydrogel-based products for chronic wound care and wellness. Its proprietary hyper-oxygenated solution platform is designed to deliver biologically relevant oxygen to tissue to support healing and functional skin recovery rather than wound closure alone. The company was founded in 2025 by Carmelo R. Montalvo, Dan Willis, Zach Richert and Derek Gonano, and in April 2026 signed a manufacturing collaboration MOU with Pure Source, an FDA-registered contract manufacturer, while retaining ownership of its IP and formulations.

A hyper-oxygenated hydrogel platform aimed at restoring skin function and reducing recurrence, rather than only closing the wound.

Funding

  • Security to be acquiredFiled Apr 17, 2026Form D
    $1.6M/ $5M

Product

Hyper-Oxygenated Solution Platform

Wound care product platform

A proprietary hydrogel formulation platform that delivers biologically relevant oxygen to wounded or compromised skin, offered in formats for medical wound care and wellness applications.

  • Hydrogel delivery of biologically relevant oxygen to tissue
  • Formats spanning both medical wound care and consumer wellness
  • Company retains full ownership of IP, formulations and product specifications

Built for

Clinicians, health systems and wound-care brands treating patients with chronic skin wounds, plus wellness brands licensing the hydrogel platform

People on file